Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to learn how well a combination of iparomlimab and tuvonralimab (QL1706), lenvatinib, radiotherapy, and hepatic arterial infusion chemotherapy (HAIC) works and how safe it is for people with hepatocellular carcinoma (HCC) that has grown into the portal vein, forming a portal vein tumor thrombus (PVTT). Participants will receive iparomlimab and tuvonralimab together with lenvatinib, radiotherapy directed at the portal vein tumor thrombus, and HAIC, which delivers chemotherapy directly through the hepatic artery. Researchers will evaluate how long the cancer remains controlled without getting worse, how much the tumors shrink, how long participants survive, and whether the treatment makes surgery possible for some participants. Treatment-related side effects will also be assessed. The study will also explore whether features in tumor tissue and blood are associated with treatment response and may help identify patients who are more likely to benefit from this treatment strategy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Potwierdzony rak wątroby (HCC)
- •Naciek raka w żyle wrotną (PVTT)
- •Bez wcześniejszego leczenia tego rodzaju nowotworu
- •Dobra funkcja wątroby (klasa Child-Pugh A lub B)
- •Pacjent nie może się poddać operacji, ale może przejść napromieniowanie
- •Wystarczająca funkcja narządów (krew, wątroba, nerki)
- •Stan ogólny pacjenta pozwala na leczenie (ECOG 0-1)
✗ Disqualifies
- •Bardzo słaby stan ogólny pacjenta (ECOG ≥2)
- •Ciężka dysfunkcja wątroby, serca lub nerek
- •Wcześniejsze leczenie tego raka (chemioterapia, immunoterapia, napromieniowanie)
- •Uczulenie na którykolwiek ze składników leczenia
- •Historia przeszczepu narządu lub komórek macierzystych
- •Trwała immunoterapia lub hormonoterapia
- •Aktywna infekcja lub niestabilna choroba układowa
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Wuhan, China
Trial contact
Jun Xue, Doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.